α-Galactosidase A knockout mice: Progressive organ pathology resembles the type 2 later-onset phenotype of fabry disease

American Journal of Pathology

Volumn 185, Issue 3, 2015, Pages 651-665

  Bangari, Dinesh S ^a   Ashe, Karen M ^a   Desnick, Robert J ^b   Maloney, Colleen ^a   Lydon, John ^a   Piepenhagen, Peter ^a   Budman, Eva ^a   Leonard, John P ^a   Cheng, Seng H ^a   Marshall, John ^a   Thurberg, Beth L ^a  

^a SANOFI   (France)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; GLOBOTRIAOSYLCERAMIDE; GLYCOSPHINGOLIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CAPILLARY EPITHELIAL CELL; CARDIOVASCULAR DISEASE; CELLS; CONTROLLED STUDY; CORNEA EPITHELIUM; CYTOPLASM; DIGESTIVE SYSTEM DISEASE; ELECTRON MICROSCOPY; ENDOTHELIUM CELL; EPITHELIUM CELL; FABRY DISEASE; FEMALE; GLOMERULUS CAPILLARY; GRAY MATTER; HEART; HEART MUSCLE CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; INTESTINE MUSCLE; KIDNEY; KIDNEY DISEASE; KIDNEY EPITHELIUM; KIDNEY TUBULE; KIDNEY TUBULE CELL; KNOCKOUT MOUSE; KUPFFER CELL; LATENT PERIOD; LIVER; LIVER CELL; LUNG ALVEOLUS EPITHELIUM; LYSOSOME; MALE; MESANGIUM CELL; MORBIDITY; MOUSE; MYENTERIC PLEXUS; NERVE CELL; NEUROPATHOLOGY; NONHUMAN; PATHOLOGY; PERIPHERAL NERVE; PHENOTYPE; PLASMA; PODOCYTE; PRIORITY JOURNAL; RETINA GANGLION CELL; SENSORY NEUROPATHY; SILVER STAINING; SKELETAL MUSCLE; SMOOTH MUSCLE FIBER; SPINAL CORD; SPINAL CORD DORSAL HORN; SPINAL GANGLION; TRIGEMINUS GANGLION; TYPE 2 LATER ONSET PHENOTYPE OF FABRY DISEASE; VASCULAR SMOOTH MUSCLE; ANIMAL; CARDIOVASCULAR SYSTEM; DISEASE COURSE; DISEASE MODEL; GENETICS; INTESTINE; METABOLISM;

ALPHA-GALACTOSIDASE; ANIMALS; CARDIOVASCULAR SYSTEM; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FABRY DISEASE; FEMALE; HUMANS; INTESTINES; KIDNEY; MALE; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; NEURONS; PHENOTYPE;

EID: 84925071355     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2014.11.004     Document Type: Article

References (48)

1. R.J. Desnick, Y.A. Ioannou, and C.M. Eng α-Galactosidase A deficiency: Fabry disease C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle, V.E. Kinzler, B. Vogelstein, The Metabolic and Molecular Bases of Inherited Disease ed 8. 2001 McGraw-Hall New York 3733 3774
2. D.P. Germain Fabry disease Orphanet J Rare Dis 5 2010 30
3. B.L. Thurberg, J.T. Fallon, R. Mitchell, T. Aretz, R.E. Gordon, and M.W. O'Callaghan Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy Circulation 119 2009 2561 2567
4. B.L. Thurberg, H. Randolph Byers, S.R. Granter, R.G. Phelps, R.E. Gordon, and M. O'Callaghan Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies J Invest Dermatol 122 2004 900 908
5. B.L. Thurberg, H. Rennke, R.B. Colvin, S. Dikman, R.E. Gordon, A.B. Collins, R.J. Desnick, and M. O'Callaghan Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy Kidney Int 62 2002 1933 1946
6. M. Elleder Subcellular, cellular and organ pathology of Fabry disease D. Elstein, G. Altarescu, M. Beck, Fabry Disease 2010 Springer London 39 80
7. W. von Scheidt, C.M. Eng, T.F. Fitzmaurice, E. Erdmann, G. Hubner, E.G. Olsen, H. Christomanou, R. Kandolf, D.F. Bishop, and R.J. Desnick An atypical variant of Fabry's disease with manifestations confined to the myocardium N Engl J Med 324 1991 395 399
8. R.J. Desnick, R. Brady, J. Barranger, A.J. Collins, D.P. Germain, M. Goldman, G. Grabowski, S. Packman, and W.R. Wilcox Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy Ann Intern Med 138 2003 338 346
9. S. Nakao, C. Kodama, T. Takenaka, A. Tanaka, Y. Yasumoto, A. Yoshida, T. Kanzaki, A.L. Enriquez, C.M. Eng, H. Tanaka, C. Tei, and R.J. Desnick Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype Kidney Int 64 2003 801 807
10. S. Nakao, T. Takenaka, M. Maeda, C. Kodama, A. Tanaka, M. Tahara, A. Yoshida, M. Kuriyama, H. Hayashibe, H. Sakuraba, and H. Tanaka An atypical variant of Fabry's disease in men with left ventricular hypertrophy N Engl J Med 333 1995 288 293
11. F. Derouiche, G. Rodier, E. Cohen, C. Boulay, P. Bronner, and F. Battaglia [Atypical phenotype of Fabry disease. Evidence of a new mutation] French. Presse Med 29 2000 1978 1980
12. Y.A. Ioannou, K.M. Zeidner, R.E. Gordon, and R.J. Desnick Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice Am J Hum Genet 68 2001 14 25
13. T. Ohshima, G.J. Murray, W.D. Swaim, G. Longenecker, J.M. Quirk, C.O. Cardarelli, Y. Sugimoto, I. Pastan, M.M. Gottesman, R.O. Brady, and A.B. Kulkarni Alpha-Galactosidase A deficient mice: a model of Fabry disease Proc Natl Acad Sci USA 94 1997 2540 2544
14. A.M. Wang, Y.A. Ionnaou, L.M. Zeidner, R.W. Gotleb, S. Dikman, C.L. Stewart, and R.J. Desnick Generation of a mouse model with α-galactosidase A deficiency (abstract) Am J Hum Genet 59 Suppl 1996 A208
15. J. Marshall, K.M. Ashe, D. Bangari, K. McEachern, W.L. Chuang, J. Pacheco, D.P. Copeland, R.J. Desnick, J.A. Shayman, R.K. Scheule, and S.H. Cheng Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease PLoS One 5 2010 e15033
16. T. Heare, N.J. Alp, D.A. Priestman, A.B. Kulkarni, P. Qasba, T.D. Butters, R.A. Dwek, K. Clarke, K.M. Channon, and F.M. Platt Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment J Inherit Metab Dis 30 2007 79 87
17. R.J. Ziegler, C. Li, M. Cherry, Y. Zhu, D. Hempel, N. van Rooijen, Y.A. Ioannou, R.J. Desnick, M.A. Goldberg, N.S. Yew, and S.H. Cheng Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease Hum Gene Ther 13 2002 935 945
18. R.J. Ziegler, M. Cherry, C.M. Barbon, C. Li, S.D. Bercury, D. Armentano, R.J. Desnick, and S.H. Cheng Correction of the biochemical and functional deficits in Fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase A Mol Ther 15 2007 492 500
19. J. Ward, M.R. Anver, J.F. Mahler, and D. Devor-Hennemann Pathology of mice commonly used in genetic engineering (C57Bl/6;129;B6,129; and FVB/n) J.M. Ward, J.F. Mahler, R.R. Maronpot, J.P. Sundberg, R.M. Frederickson, Pathology of Genetically Engineered Mice 2000 Iowa State University Press Ames, IA 161 182
20. T. Ohshima, R. Schiffmann, G.J. Murray, J. Kopp, J.M. Quirk, S. Stahl, C.C. Chan, P. Zerfas, J.H. Tao-Cheng, J.M. Ward, R.O. Brady, and A.B. Kulkarni Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice Proc Natl Acad Sci USA 96 1999 6423 6427
21. S.M. Meehan, T. Junsanto, J.J. Rydel, and R.J. Desnick Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications Am J Kidney Dis 43 2004 164 171
22. K. Deniz, A. Yurci, A. Yaʇbasan, F. Tekelioʇlu, S. Gursoy, and K. Güven Colonic involvement in Fabry disease Int J Surg Pathol 19 2011 777 778
23. M. Elleder, V. Bradová, F. Smíd, M. Buděsínský, K. Harzer, B. Kustermann-Kuhn, J. Ledvinová, Bělohlávek, V. Král, and V. Dorazilová Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy Virchows Arch A Pathol Anat Histopathol 417 1990 449 455
24. T.C. Iancu The ultrastructural spectrum of lysosomal storage diseases Ultrastruct Pathol 16 1992 231 244
25. C.M. Eng, M. Banikazemi, R.E. Gordon, M. Goldman, R. Phelps, L. Kim, A. Gass, J. Winston, S. Dikman, J.T. Fallon, S. Brodie, C.B. Stacy, D. Mehta, R. Parsons, K. Norton, M. O'Callaghan, and R.J. Desnick A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies Am J Hum Genet 68 2001 711 722
26. C.M. Eng, N. Guffon, W.R. Wilcox, D.P. Germain, P. Lee, S. Waldek, L. Caplan, G.E. Linthorst, R.J. Desnick International Collaborative Fabry Disease Study Group Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease N Engl J Med 345 2001 9 16
27. T. Tabira, I. Goto, Y. Kuroiwa, and M. Kikuchi Neuropathological and biochemical studies in Fabry's disease Acta Neuropathol 30 1974 345 354
28. L.G. Rodrigues, M.J. Ferraz, D. Rodrigues, M. Pais-Vieira, D. Lima, R.O. Brady, M.M. Sousa, and M.C. Sá-Miranda Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice Neurobiol Dis 33 2009 48 56
29. M. Banikazemi, T. Ullman, and R.J. Desnick Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy Mol Genet Metab 85 2005 255 259
30. C.I. Jack, A.I. Morris, D.G. Nasmyth, and N. Carroll Colonic involvement in Fabry's disease Postgrad Med J 67 1991 584 585
31. C.M. Eng, J. Fletcher, W.R. Wilcox, S. Waldek, C.R. Scott, D.O. Sillence, F. Breunig, J. Charrow, D.P. Germain, K. Nicholls, and M. Banikazemi Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry J Inherit Metab Dis 30 2007 184 192
32. M. Uchino, E. Uyama, H. Kawano, J. Hokamaki, K. Kugiyama, Y. Murakami, H. Yasue, and M. Ando A histochemical and electron microscopic study of skeletal and cardiac muscle from a Fabry disease patient and carrier Acta Neuropathol 90 1995 334 338
33. H. Askari, C.R. Kaneski, C. Semino-Mora, P. Desai, A. Ang, D.E. Kleiner, L.T. Perlee, M. Quezado, L.E. Spollen, B.A. Wustman, and R. Schiffmann Cellular and tissue localization of globotriaosylceramide in Fabry disease Virchows Arch 451 2007 823 834
34. G.L. Kolling, F. Obata, L.K. Gross, and T.G. Obrig Immunohistologic techniques for detecting the glycolipid Gb(3) in the mouse kidney and nervous system Histochem Cell Biol 130 2008 157 164
35. M. Przybylska, I.H. Wu, H. Zhao, R.J. Ziegler, J.D. Tousignant, R.J. Desnick, R.K. Scheule, S.H. Cheng, and N.S. Yew Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors J Gene Med 6 2004 85 92
36. M. Elleder Sequelae of storage in Fabry disease-pathology and comparison with other lysosomal storage diseases Acta Paediatr Suppl 92 2003 46 53
37. H. Teraguchi, T. Takenaka, A. Yoshida, S. Taguchi, K. Ninomiya, H. Yoshida, M. Horinouchi, S. Yonezawa, S. Nakao, S. Minagoe, and S. Tei [End-stage cardiac manifestations and autopsy findings in patients with cardiac Fabry disease] Japanese J Cardiol 43 2004 98 99
38. M. Namdar, C. Gebhard, R. Studiger, Y. Shi, P. Mocharla, C. Schmied, P. Brugada, T.F. Luscher, and G.G. Camici Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease PLoS One 7 2012 e36373
39. J.T. Clarke The glycosphingolipids of human plasma lipoproteins Can J Biochem 59 1981 412 417
40. C.H. Schweppe, P. Hoffmann, J.R. Nofer, G. Pohlentz, M. Mormann, H. Karch, A.W. Friedrich, and J. Müthing Neutral glycosphingolipids in human blood: a precise mass spectrometry analysis with special reference to lipoprotein-associated Shiga toxin receptors J Lipid Res 51 2010 2282 2294
41. M.C. Camus, M.J. Chapman, P. Forgez, and P.M. Laplaud Distribution and characterization of the serum lipoproteins and apoproteins in the mouse, Mus musculus J Lipid Res 24 1983 1210 1228
42. M.A. Psotka, F. Obata, G.L. Kolling, L.K. Gross, M.A. Saleem, S.C. Satchell, P.W. Mathieson, and T.G. Obrig Shiga toxin 2 targets the murine renal collecting duct epithelium Infect Immun 77 2009 959 969
43. D.J. Goldsmith, I.S. Roberts, and N.P. Mallick Tingling extremities in a young man Postgrad Med J 72 1996 380 382
44. S.A. Cilmi, B.J. Karalius, W. Choy, R.N. Smith, and J.R. Butterton Fabry disease in mice protects against lethal disease caused by Shiga toxin-expressing enterohemorrhagic Escherichia coli J Infect Dis 194 2006 1135 1140
45. Y. Fujii, S. Numata, Y. Nakamura, T. Honda, K. Furukawa, T. Urano, J. Wiels, M. Uchikawa, N. Ozaki, S. Matsuo, Y. Sugiura, and K. Furukawa Murine glycosyltransferases responsible for the expression of globo-series glycolipids: cDNA structures, mRNA expression, and distribution of their products Glycobiology 15 2005 1257 1267
46. M. Devor Unexplained peculiarities of the dorsal root ganglion Pain 82 Suppl 1 1999 S27 S35
47. M. Spada, S. Pagliardini, M. Yasuda, T. Tukel, G. Thiagarajan, H. Sakuraba, A. Ponzone, and R.J. Desnick High incidence of later-onset Fabry disease revealed by newborn screening Am J Hum Genet 79 2006 31 40
48. Y.H. Chien, O.A. Bodamer, S.C. Chiang, H. Mascher, C. Hung, and W.L. Hwu Lyso-globotriaosylsphingosine (lyso-Gb3) levels in neonates and adults with the Fabry disease later-onset GLA IVS4+919G>A mutation J Inherit Metab Dis 36 2013 881 885